Market Research Industry Reports

Market Access Impact (US) [NSCLC]

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Eliminating market barriers could help lower-ranked brands a narrow lead

Three brands are way ahead in the US non-small cell lung cancer (NSCLC) market, thanks in part to market barriers that prevent oncologists from prescribing competing treatments. Eliminating these barriers won’t be enough for lower-ranked brands to catch up to the market leaders, but it could give a few of them the market share bump they need to overtake their closest rivals.

Get the details in Market Access Impact: NSCLC (US).

You’ll see how widely prescribed your brand is, and learn how 7 barriers affect your market share. You’ll also find out how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 100 US-based medical oncologists and primary care physicians, the report covers 13 major therapies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck & Co., Novartis, Pfizer/Merck Group, and Roche

Not your market? Click here to see the EU5 report

Top Takeaways

Barriers affect nearly 20% of prescriptions: High cost is the biggest issue, but each of the 6 other surveyed barriers affects roughly the same number of prescriptions.
Three brands dominate: Their respective market shares are at most 4% apart. However, significantly more doctors prescribe the top two brands than the third-place runner-up.
A battle of inches: Barriers only have a modest effect on market share, but it’s enough to hold at least two brands back. Eliminating barriers would push each of them up by one spot.
Problem areas: Some barriers have an outsized effect on some brands, e.g., high cost is the issue for one leading brand, while two lower-ranked rivals, have big reimbursement problems.
Barrier effect is widespread: At least 50% of doctors experience one or more barriers with every surveyed brand.
Overall perception is good: Most doctors either prescribe, or would consider prescribing all of the surveyed brands, and no more than 5% of doctors are unaware of any given brand.

Insight into 13 Major NSCLC Drugs

Avastin (bevacizumab; Roche)
Alecensa (alectinib; Roche)
Cyramza (ramucirumab; Eli Lilly)
Gilotrif (afatinib; Boehringer Ingelheim)
Iressa (gefitinib; AstraZeneca)
Keytruda (pembrolizumab; Merck & Co.)
Opdivo (nivolumab; Bristol-Myers Squibb)
Portrazza (necitumumab; Eli Lilly)
Tagrisso (osimertinib; AstraZeneca)
Tarceva (erlotinib; Roche)
Tecentriq (atezolizumab; Roche)
Xalkori (crizotinib; Pfizer/Merck Group)
Zykadia (ceritinib; Novartis)

Exploring Market Access Barriers

Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with NSCLC in total in the last month

1. What are market barriers?
2. About this report
3. About the survey
4. Brands included in the survey
5. Executive summary


MEED: Middle East & North Africa (MENA) Oil and Gas Market 2018

MEED: Middle East & North Africa (MENA) Oil and Gas Market 2018While projects worth more than $250bn are already under execution as of November 2017, the MENA region is expected

USD 4500View Report

UK Power Market Outlook to 2030, Update 2018 - Market Trends, Regulations, and Competitive Landscape

UK Power Market Outlook to 2030, Update 2018 - Market Trends, Regulations, and Competitive LandscapeThis report elaborates the United Kingdoms power market structure and provides historical and forecast numbers for

USD 2500View Report

Market Access Impact: Melanoma (US) 2018

Market barriers affect just under a fifth of melanoma prescriptions. Is your brand losing outIn the US, where market barriers affect just under a fifth of all melanoma prescriptions, the

USD 5345View Report

Market Access Impact: Melanoma (EU5) 2018

Market barriers affect a fifth of melanoma prescriptions. Is your brand losing outIn the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow

USD 5345View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 5145
  • Enterprise Wide Licence    USD 7725
$ 5145

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube